Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Bajorin
    Bajorin
  2. Sheinfeld
    Sheinfeld
  3. Motzer
    Motzer
  4. Rosenberg
    Rosenberg
  5. Bochner
    Bochner
  6. Bosl
    Bosl
  7. Dalbagni
    Dalbagni
  8. Carver
    Carver
  9. Herr
    Herr
  10. Feldman
    Feldman

Groups

  1. Department of Medicine (58)
  2. Genitourinary Oncology Service (58)
  3. Solid Tumor Oncology Division (58)
  4. Surgery (39)
  5. Urology (39)
  6. Survivorship Research (27)
  7. Department of Pathology and Laboratory Medicine (15)
  8. Epidemiology and Biostatistics (12)
  9. Biostatistics Service (10)
  10. GSK Faculty (8)
Search Within
  1. "Dean Bajorin"
Formats
  1. Journal Article (50)
  2. Correspondence (4)
  3. Meeting Abstract (3)
  4. Editorial (1)
Groups
  1. Department of Medicine (58)
  2. Genitourinary Oncology Service (58)
  3. Solid Tumor Oncology Division (58)
  4. Surgery (39)
  5. Urology (39)
  6. Survivorship Research (27)

More Groups

People
  1. Dean Bajorin (58)
  2. George Bosl (19)
  3. Joel Sheinfeld (19)
  4. Jonathan Rosenberg (17)
  5. Robert Motzer (17)
  6. Bernard Bochner (15)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (1)
  4. 2021 (4)
  5. 2020 (7)
  6. 2019 (2)

More Years

Publications
  1. Journal of Urology (25)
  2. Urology (14)
  3. European Urology (12)
  4. Lancet Oncology (4)
  5. Lancet (2)
  6. Critical Reviews in Oncology/Hematology (1)

Results (58)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular, immunohistochemical and clinical determinants of urothelial carcinoma of the bladder with nested subtype
    Meeting Abstract

    Koll, F. J.; Basar, M.; Chen, Z.; Tin, A. L.; Alam, S. M.; Tallman, J. E.; Clinton, T. N.; Whiting, K.; Chen, J. F.; Sarungbam, J.; more...
    European Urology (2024)

    Fulltext@MSK | Save
  • Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial
    Journal Article

    Necchi, A.; Roumiguié, M.; Kamat, A. M.; Shore, N. D.; Boormans, J. L.; Esen, A. A.; Lebret, T.; Kandori, S.; Bajorin, D. F.; Krieger, L. E. M.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Genome-wide association study of bladder cancer reveals new biological and translational insights
    Journal Article

    Koutros, S.; Kiemeney, L. A.; Pal Choudhury, P.; Milne, R. L.; Lopez de Maturana, E.; Ye, Y.; Joseph, V.; Florez-Vargas, O.; Dyrskjøt, L.; Figueroa, J.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Disease-free survival analysis for patients with high-risk muscle-invasive urothelial carcinoma from the randomized CheckMate 274 trial by PD-L1 combined positive score and tumor cell score
    Journal Article

    Galsky, M. D.; Bajorin, D. F.; Witjes, J. A.; Gschwend, J. E.; Tomita, Y.; Nasroulah, F.; Li, J.; Collette, S.; Valderrama, B. P.; Grimm, M. O.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • Final results of a phase I trial of WST-11 (TOOKAD Soluble) vascular-targeted photodynamic therapy for upper tract urothelial carcinoma
    Journal Article

    Yip, W.; Sjoberg, D. D.; Nogueira, L. M.; Tracey, A. T.; Alvim, R. G.; Reisz, P. A.; Demac, Q.; Benfante, N. E.; Vanden Berg, R. W.; Kim, K.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • Survival impact of variant histology diagnosis in upper tract urothelial carcinoma
    Journal Article

    Nogueira, L. M.; Yip, W.; Assel, M. J.; Tracey, A. T.; Wong, N. C.; Alvim, R. G.; Al-Ahmadie, H.; Bajorin, D. F.; Coleman, J. A.
    Journal of Urology (2022)

    Fulltext@MSK | Save
  • Re: Utility of routine preoperative (18)F-fluorodeoxyglucose positron emission tomography/computerized tomography in identifying pathological lymph node metastases at radical cystectomy - Reply by authors
    Correspondence

    Dason, S.; Wong, N. C.; Donahue, T. F.; Meier, A.; Zheng, J.; Mannelli, L.; Di Paolo, P. L.; Dean, L. W.; McPherson, V. A.; Rosenberg, J. E.; more...
    Journal of Urology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life with adjuvant nivolumab vs. placebo after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 checkmate 274 trial
    Meeting Abstract

    Gschwend, J. E.; Bajorin, D.; Galsky, M.; Broughton, E.; Braverman, J.; Koon, H.; Maira-Arce, M.; Hamilton, M.; Shi, L.; Guo, S.; more...
    European Urology (2021)

    Fulltext@MSK | Save
  • Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study
    Journal Article

    Balar, A. V.; Kamat, A. M.; Kulkarni, G. S.; Uchio, E. M.; Boormans, J. L.; Roumiguié, M.; Krieger, L. E. M.; Singer, E. A.; Bajorin, D. F.; Grivas, P.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Utility of routine preoperative (18)F-fluorodeoxyglucose positron emission tomography/computerized tomography in identifying pathological lymph node metastases at radical cystectomy. Reply
    Correspondence

    Dason, S.; Wong, N. C.; Donahue, T. F.; Meier, A.; Zheng, J.; Mannelli, L.; Di Paolo, P. L.; Dean, L. W.; McPherson, V. A.; Rosenberg, J. E.; more...
    Journal of Urology (2021)

    Fulltext@MSK | Save